Qualigen Therapeutics, Inc.
QLGNNASDAQHealthcare
$3.21
+$0.17(+5.59%)
Market Cap$5430810
P/E Ratio—
52W High$8.81
52W Low$1.61
Qualigen Therapeutics, Inc. (QLGN) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · QLGN · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.01B | $0.00B | $0.01B |
| Cost of Revenue | $0.00B | $0.00B | $0.01B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | ($0.00B) | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | -0.09% | 13.66% | 23.37% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.01B | $0.01B | $0.01B |
| G&A Expenses | $0.01B | $0.00B | $0.01B | $0.01B | $0.01B |
| Total Operating Expenses | $0.01B | $0.01B | $0.01B | $0.02B | $0.02B |
| Operating Income | ($0.01B) | ($0.01B) | ($0.01B) | ($0.02B) | ($0.02B) |
| Operating Margin %(computed) | — | — | -217.20% | -360.03% | -400.85% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.02B) | ($0.01B) | ($0.01B) | ($0.02B) | ($0.02B) |
| Income Tax Expense | $0.00B | $0.00B | ($0.00B) | ($0.00B) | $0.00B |
| Net Income | ($0.02B) | ($0.01B) | ($0.01B) | ($0.02B) | ($0.02B) |
| Net Margin %(computed) | — | — | -257.79% | -422.08% | -316.55% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-8.11 | $-17.28 | $-2.46 | $-5.48 | $-6.10 |
| Wtd Avg Shares | 0.00B | 0.00B | 0.01B | 0.00B | 0.00B |
| EBITDA | ($0.01B) | ($0.01B) | ($0.01B) | ($0.01B) | ($0.02B) |
| EBITDA Margin %(computed) | — | — | -217.12% | -277.74% | -395.15% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Qualigen Therapeutics, Inc. data
About Qualigen Therapeutics, Inc. (QLGN) Income Statement
Qualigen Therapeutics, Inc. (QLGN) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, QLGN reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.02B) — a net profit margin of —.
Frequently asked questions
QLGN · 4 questionsQualigen Therapeutics, Inc. (QLGN) reported revenue of $0.00B for 2025, down —% year-over-year.
QLGN revenueQLGN salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08